Merger activity increased last week with four new deals announced and two deals closing. Out of the four deals announced, three were cash deals and one was an all-stock deal.
The acquisition of Forty Seven ([[FTSV]]) by Gilead Sciences ([[GILD]]) was the first deal announced last week. FTSV stock rocketed after the deal was announced. Gilead agreed to pay $95.50 for each Forty Seven share, a 64.7 premium to Friday's closing price of $58.00. This deal will help Gilead expand its cancer drug pipeline. Through the addition of Forty Seven’s investigational lead product candidate, magrolimab,